The Role of Cytokine Therapy in Metastatic Renal Cell Cancer

European Urology, Supplements

Volumn 6, Issue 10, 2007, Pages 658-664

  Johannsen, Manfred ^a   Brinkmann, Olaf A ^b   Bergmann, Lothar ^c   Heinzer, Hans ^d   Steiner, Thomas ^e   Ringsdorf, Martin ^a   Römer, Andreas ^a   Roigas, Jan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Cytokines; Immunotherapy; Metastatic; Renal cell cancer

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; CAPECITABINE; FLUOROURACIL; GAMMA1B INTERFERON; INTERFERON; INTERLEUKIN 2; ISOTRETINOIN; MEDROXYPROGESTERONE ACETATE; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; VINBLASTINE;

APPETITE; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DEPRESSION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; FATIGUE; FEVER; FLUID RETENTION; HEART INFARCTION; HORMONAL THERAPY; HUMAN; HYPOTENSION; IMMUNOTHERAPY; KIDNEY CANCER; LIVER FAILURE; LOW DRUG DOSE; LUNG EDEMA; META ANALYSIS; METASTASIS; MONOTHERAPY; MYALGIA; OLIGURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

EID: 34247267208     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2007.03.001     Document Type: Article

References (41)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. Motzer R.J., and Mazumdar M. Predicting survival of patients with metastatic renal cell carcinoma. Urologe A 43 Suppl 3 (2004) 135-136
3. Chow W.H., Devesi S., and Warren J.L. Rising incidence of renal cell cancer in the United States. JAMA 281 (1999) 17-19
4. Patard J.J., Kim H.L., Lam J.S., et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 22 (2004) 3316-3322
5. Motzer R.J., Mazumdar M., Bacik J., et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17 (1999) 2530-2540
6. Motzer R.J., Bacik J., Schwartz L.H., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22 (2004) 454-463
7. Flanigan R.C., Salmon S.E., Blumenstein B.A., et al. Nephrectomy followed by interferon α-2b compared with interferon α-2b alone for metastatic renal-cell cancer. N Engl J Med 345 (2001) 1655-1659
8. Mickisch G.H., Garin A., van Poppel H., et al. Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon α alone in metastatic renal-cell carcinoma: a randomized trial. Lancet 358 (2001) 966-970
9. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
10. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
11. Hudes G., Carducci M., Tomczak P., et al. A phase 3, randomized 3-arm study of temsirolimus (TEMSR) or interferon-alfa (IFN) or the combination (TEMSR + IFN) in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma. J Clin Oncol 24 18 Suppl II (2006) 930s
12. Yang J.C., and Childs R. Immunotherapy for renal cell cancer. J Clin Oncol 24 (2006) 5576-5583
13. Roigas J., Johannsen M., Ringsdorf M., et al. Allogeneic stem cell transplantation for patients with metastatic renal cell carcinoma. Expert Rev Anticancer Ther 6 (2006) 1449-1458
14. Dorr R.T. Interferon-alpha in malignant and viral diseases: a review. Drugs 45 (1993) 177-211
15. Gleave M.E., Elhilali M., Fradet Y., et al. Interferon γ-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 338 (1998) 1265-1271
16. Medical Research Council Renal Cancer Collaborators (MRCRCC). Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Lancet 353 (1999) 14-17
17. Coppin C., Porzolt F., Kumpf J., et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 3 (2003) 1-46
18. Coppin C, Porzolt F, Wilt T, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005;1:CD001425.
19. Motzer R.J., Murphy B.A., Bacik J., et al. Phase III trial of Interferon-α-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 18 (2000) 2972-2980
20. Aass N., De Mulder P.H., Mickisch G.H., et al. Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J Clin Oncol 23 (2005) 4172-4178
21. Whittington R., and Faulds D. Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 46 (1993) 446-514
22. Yang J.C., Sherry R.M., Steinberg S.M., et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cell cancer. J Clin Oncol 21 (2003) 3127-3132
23. Negrier S., Perol D., Ravaud A., et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial. J Clin Oncol 23 June 1 Suppl (2005) 4511
24. Negrier S., Escudier B., Lasset C., et al. Recombinant human interleukin-2, recombinant human interferon α-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 338 (1998) 1272-1278
25. McDermott D., Retgan M.M., Clark J.I., et al. Randomized phase III trial of high-dose interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23 (2005) 133-141
26. Amato R.J. Chemotherapy for renal cell carcinoma. Semin Oncol 27 (2000) 177-186
27. Pyrhonen S., Salminen E., Ruutu M., et al. Prospective randomized trial of interferon α-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17 (1999) 2859-2867
28. Fossa S.D., Martinelli G., Otto U., et al. Recombinant interferon α-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center Phase III study. Ann Oncol 3 (1992) 301-305
29. Neidhart J.A., Anderson S.A., Harris J.E., et al. Vinblastine fails to improve response of renal cancer to interferon α-n1: high response rate in patients with pulmonary metastases. J Clin Oncol 9 (1991) 832-836
30. Kriegmair M., Oberneder R., and Hofstetter A. Interferon α and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology 45 (1995) 758-762
31. Kase S., Kubota T., Watanabe M., et al. Recombinant human interferon α-2a increases 5-fluorouracil efficacy by elevating fluorouridine concentration in tumor tissue. Anticancer Res 14 (1994) 1155-1159
32. Negrier S., Caty A., Lesimple T., et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon α with or without fluorouracil. J Clin Oncol 18 (2000) 4009-4015
33. Atzpodien J., Kirchner H., Illiger H.J., et al. IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized trial. Br J Cancer 85 (2001) 1130-1136
34. Atzpodien J., Kirchner H., Jonas U., et al. Interleukin-2 and interferon-α-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Cell Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22 (2004) 1188-1194
35. Atzpodien J., Kirchner H., Rebmann U., et al. Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 95 (2006) 463-469
36. Rosenberg S.A., Yang J.C., White D.E., et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2. Ann Surg 228 (1998) 307-319
37. Patard J.-J., Rioux-Leclercq N., and Fergelot P. Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 49 (2006) 633-643
38. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524
39. Ronnen E.A., Kondagunta G.V., Ishill N., et al. Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer 107 (2006) 2617-2621
40. Motzer R.J., Bacik J., Mariani T., et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 20 (2002) 2376-2381
41. Atkins M., Regan M., McDermott D., et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11 (2005) 3714-3721